ESMO 2019 | TNBC treatment: platinum-based therapy and PARP inhibition
Véronique Dieras
Véronique Dieras, MD, Eugène Marquis Center, Rennes, France, talks about BRCA mutations in triple-negative breast cancer (TNBC) and the promising response to cytotoxic platinum-based chemotherapy and PARP inhibitors. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.
Related videos

BROCADE3: veliparib with carboplatin/paclitaxel in HER2-/BRCA+ advanced breast cancer
Véronique Dieras

HER-2 conversion: a phenomenon in trastuzumab resistance
Russell Petty

Real-world clinical outcomes in metastatic breast cancer patients treated with palbociclib
Felice Musicco

IMpower110: atezolizumab vs chemo in PD-L1–selected NSCLC
David Spigel

Targeted therapy in TNBC
Peter Schmid
More from Véronique Dieras